United States · FDA National Drug Code directory
Baxdela
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 70842-102_fcc371f3-3214-4036-8834-33337e7cae0f
- Product NDC
- 70842-102
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- delafloxacin meglumine
- Labeler
- Melinta Therapeutics, LLC
- Marketing category
- NDA
- Marketing start / end (source format)
- 20170619
- Source listing expiry
- 20261231
Source-listed ingredients
- DELAFLOXACIN MEGLUMINE — 300 mg/10.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 VIAL, GLASS in 1 CARTON (70842-102-03) / 10.5 mL in 1 VIAL, GLASS (70842-102-01) · 70842-102-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →